Open AccessEarly Supported Discharge for patients with febrile neutropenia – Experience at a large district hospital in the UK
Author(s) -
C Brunner,
J. Botten,
Nic Wennike,
Linda Ford,
Katherine Michaels,
Angela Stephens,
Robert S. Baker
Publication year - 2019
Publication title -
acute medicine
Language(s) - English
Resource type - Journals
eISSN - 1747-4892
pISSN - 1747-4884
DOI - 10.52964/amja.0742
Subject(s) - medicine , febrile neutropenia , sepsis , neutropenia , emergency medicine , intensive care medicine , chemotherapy
Neutropenic sepsis can be life threatening, with mortality 2-21%. The heterogeneity of patients referred with “suspected neutropenic sepsis” has led to strategies being developed to risk-stratify patients and identify those with a low risk of septic complications that could be managed in the outpatient setting, such as The Multinational Association for Supportive Care in Cancer score (MASCC). Outcomes for patients referred with suspected neutropenic sepsis were assessed before and after use of MASCC guided early-supported discharge. 50/123 (41%) patients over 24 months were eligible for early-supported discharge. 26/50 patients had same-day discharge, 14 had overnight admission, 8 stayed 2 nights and 2 stayed 3 nights. Patients received on average 2 follow-up telephone consultations. There were 5 readmissions (10%) and no adverse events. In comparison group; 8 patients over 3-months would have been suitable, potentially saving 40 bed-days. This shows MASCC guided early-supported discharge is safe and cost-effective.